Popular Posts Last 7 days_$type=three$meta=0$snip=0$rm=0$count=9$show=/search/label/Popular

Popular Posts Last 30 days_$type=three$meta=0$snip=0$rm=0$count=9$show=/search/label/Popular

Popular Posts Last year_$type=three$meta=0$snip=0$rm=0$count=9$show=/search/label/Popular

Popular Posts All time_$type=three$meta=0$snip=0$rm=0$count=9$show=/search/label/Popular

Islamophobia_$type=carousel$h=350$show=/search/label/Muslim%20World

Saudi Arabia$type=two$count=2$h=250$space=1$icon=1$m=0$sn=0$rm=0$show=/search/label/Muslim%20World

Iran_$type=three$count=3$h=250$space=1$icon=1$m=0$sn=0$rm=0$show=/search/label/Muslim%20World

Palestine$type=three$author=hide$comment=hide$rm=hide$date=hide$show=/search/label/Muslim%20World

Novartis sees bright future for eye unit

SHARE:

The logo of Swiss pharmaceutical company Novartis is seen on its headquarters building in Basel, Switzerland.

ZURICH -  Swiss pharmaceutical giant Novartis said Tuesday a strategic review of its eye care unit showed that Alcon can deliver strong growth, but that a possible spin-off or listing is at least two years away.

While a decision on Alcon's fate had been expected by the end of this year, the firm said it wanted further quarters of sales growth and better profit margins before taking a decision, meaning that no action was likely before the first half of 2019.

Novartis also released Tuesday quarterly results which showed a 7 percent increase in net profit to $2.08 billion on a 2 percent increase in sales to $12.4 billion.

But over the first nine months of the year net profit was down 1 percent to $5.7 billion.

Novartis confirmed its annual outlook of sales similar to the $48.5 billion registered last year and operating profits near or slightly below the $12.9 billion recording in 2016.

The firm said it had made significant progress in its strategic review of Alcon, part of which was a decision to transfer over-the-counter Novartis ophthalmic products into the division beginning in January.

As part of the review it "updated Alcon's strategic plan which confirms that it has the potential to grow sales at or above market while delivering profitability at least in line with the industry," the company said in a statement.

Sales rose by 6 percent in the third quarter to $1.5 billion. Over nine months, the rise in sales was 3 percent to $4.5 billion.

"Alcon delivered strong growth in both sales and core operating income," chief executive Joseph Jimenez said in the statement.

Numerous analysts had doubted Novartis would come to a decision on Alcon's fate by the end of the year given the upcoming change in leadership.

Jimenez, who has been chief executive since 2010, is set to hand over the reins at the end of January to Vasant Narasimhan, who has been the firm's global head of drug development and chief medical officer since February last year

COMMENTS

Name

Ads,5,Afghanistan,75,Africa,26,Americas,5,Animals,36,Argentina,1,Asia,235,Australia,11,Austria,5,Bahrain,2,Bangladesh,18,Barcelona,1,Belgium,3,Brunei,1,Business,1300,Canada,4,Catalan,80,China,118,Cuba,3,Czech Republic,3,DR Congo,1,Egypt,22,Ethiopia,1,Europe,237,Fitness,14,France,26,Germany,37,Headlines,11,Health,169,Hillary Clinton,199,Hong Kong,2,Hungary,1,Iceland,1,India,104,Indonesia,9,International,75,Iran,77,Iraq,77,Ireland,2,Islamophobia,19,Israel,10,Italy,3,Japan,36,Jordan,1,Kenya,7,Kosovo,1,Kuwait,3,Lebanon,2,Libya,2,Lifestyle,302,Lithuania,1,Malawi,1,Malaysia,15,Malta,1,Maxico,3,Middle East,127,Muslim World,598,Myanmar,35,Nawaz Sharif,5,Nepal,3,Netherlands,2,New Zealand,9,Niger,1,Nigeria,2,Nobel Prize,81,North Korea,53,Norway,1,Opinion,26,Pakistan,1036,Palestine,36,Philippine,16,Pics,66,Poland,3,Popular,1,Qatar,93,Rohingya,118,Russia,45,Rwanda,1,Saudi Arabia,83,Science,144,Serbia,2,Showbiz,350,Somalia,4,South Africa,1,South Korea,7,Spain,60,Sports,1311,Sudan,1,Sweden,1,Switzerland,2,Syria,112,Taiwan,2,Technology,449,Thailand,5,Today IN History,24,Top News,994,Tunisia,1,Turkey,77,U.S.,301,UAE,21,UK,51,Ukrain,2,Venezuela,4,Videos,75,Vietnam,2,World,4824,Yemen,21,Zimbabwe,2,
ltr
item
Muslim Global: Novartis sees bright future for eye unit
Novartis sees bright future for eye unit
Swiss pharmaceutical giant Novartis said Tuesday a strategic review of its eye care unit showed that Alcon can deliver strong growth, but that a possible spin-off or listing is at least two years away. While a decision on Alcon's fate had been expected by the end of this year, the firm said it wanted further quarters of sales growth and better profit margins before taking a decision, meaning that no action was likely before the first half of 2019.
https://3.bp.blogspot.com/-NfgETx7dNuk/We8GId0NVsI/AAAAAAAAlP0/B0-TWgGp5-w_wg_kfK-bcMJCVRZ0ZjTAgCLcBGAs/s640/Novartis%2Bsees%2Bbright%2Bfuture%2Bfor%2Beye%2Bunit.jpg
https://3.bp.blogspot.com/-NfgETx7dNuk/We8GId0NVsI/AAAAAAAAlP0/B0-TWgGp5-w_wg_kfK-bcMJCVRZ0ZjTAgCLcBGAs/s72-c/Novartis%2Bsees%2Bbright%2Bfuture%2Bfor%2Beye%2Bunit.jpg
Muslim Global
http://www.muslimglobal.com/2017/10/novartis-sees-bright-future-for-eye-unit.html
http://www.muslimglobal.com/
http://www.muslimglobal.com/
http://www.muslimglobal.com/2017/10/novartis-sees-bright-future-for-eye-unit.html
true
616431133175714168
UTF-8
Loaded All Posts Not found any posts VIEW ALL Readmore Reply Cancel reply Delete By Home PAGES POSTS View All RECOMMENDED FOR YOU LABEL ARCHIVE SEARCH ALL POSTS Not found any post match with your request Back Home Sunday Monday Tuesday Wednesday Thursday Friday Saturday Sun Mon Tue Wed Thu Fri Sat January February March April May June July August September October November December Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec just now 1 minute ago $$1$$ minutes ago 1 hour ago $$1$$ hours ago Yesterday $$1$$ days ago $$1$$ weeks ago more than 5 weeks ago Followers Follow THIS CONTENT IS PREMIUM Please share to unlock Copy All Code Select All Code All codes were copied to your clipboard Can not copy the codes / texts, please press [CTRL]+[C] (or CMD+C with Mac) to copy